|
| |
MucositisMucositis is the painful inflammation and ulceration of the mucous membranes lining the digestive tract, usually as an adverse effect of chemotherapy and radiotherapy treatment for cancer. Oral and gastrointestinal mucositis can affect up to 100% of patients undergoing high-dose chemotherapy and hematopoietic stem cell transplantation, 80% of patients with malignancies of the head and neck receiving radiotherapy, and a wide range of patients receiving chemotherapy. Alimentary track mucositis increases mortality and morbidity and contributes to rising health care costs.For most cancer treatment, about 5-15% of patients get mucositis. However, with 5-flurouracil , up to 40% get mucocitis, and 10-15% get grade 3-4 oral mucositis. Iirinotecan is associated with severe GI mucositis in over 20% of patients. 75-85% of bone marrow transplantation recipients experience mucositis, of which oral mucositis is the most common and most debilitating, especially when melphalan is used. In grade 3 oral mucositis, the patient is unable to eat solid food, and in grade 4, the patient is unable to consume liquids as well.[Rubenstein]Radiotherapy to the head and neck or to the pelvis or abdomen is associated with Grade 3 and Grade 4 oral or GI mucositis, respectively, often exceeding 50% of patients. Among patients undergoing head and neck radiotherapy, pain and decreased oral function may persist long after the conclusion of therapy. Fractionated radiation dosage increases the risk of mucositis to > 70% of patients in most trials. Oral mucositis is particularly profound and prolonged among HSCT recipients who receive total-body irradiation.[Rubenstein] (From the Wikpedia article Mucositis.) Download PDF containing detailed information.
Recent Publications on Mucositis: |  |
Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study.
BEAM is a widely used conditioning regimen for relapsed/refractory... | 10th November, 2009
| Department of Oncology, Oncohematology and Bone Marrow Transplantation
| Bone Marrow Transplant. 2009 Nov 9.
DOI Direct Link |
Concurrent control study of different radiotherapy for primary nasopharyngeal carcinoma: intensity-modulated radiotherapy versus conventional radiotherapy.
Background and Objective: Intensity-modulated radiotherapy (IMRT) has... | 10th November, 2009
| Department of Radiation Oncology, Teaching Hospital of Fujian Medical
| Chin J Cancer. 2009 Nov 5;28(11):1143-8.
|
Perioral abscess associated with isotretinoin.
Severe scarring acne is frequently treated with isotretinoin. Patients... | 10th November, 2009
| University of Miami, Department of Dermatology, Miami, FL, USA.
| J Drugs Dermatol. 2009 Nov;8(11):1034-6.
|
Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck.
BACKGROUND: Panitumumab has the potential to improve the therapeutic ratio... | 7th November, 2009
| Division of Hematology-Oncology, Department of Medicine, Massachusetts
| Ann Oncol. 2009 Nov 5.
DOI Direct Link |
The Potential Clinical Impact of Probiotic Treatment for the Prevention and/or Anti-Inflammatory Therapeutic Effect Against Radiation Induced Intestinal Mucositis. A Review.
Although pelvic radiotherapy, either alone or combined with chemotherapy,... | 7th November, 2009
| Radiotherapy Department, Attikon University Hospital, Medical School of
| Recent Pat Inflamm Allergy Drug Discov. 2009 Nov 1.
|
→View more research publications. |
Press Releases About Mucositis:
|
 |
| New Research Shows Promise in Using Traditional Research Methods to Assess Efficacy of Complementary Therapies |
12th November, 2009 |
Children's Hospitals and Clinics of Minnesota |
MINNEAPOLIS/ST. PAUL, Nov. 12 /PRNewswire/ -- New research findings presented today at the Society for Integrative Oncology's (SIO) Sixth International Conference in New York show promise in
|
| Access Pharmaceuticals Provides Update on Global Launch of MuGard(TM) |
27th May, 2009 |
Access Pharmaceuticals, Inc. |
NEW FDA-APPROVED TREATMENT FOR ORAL MUCOSITIS
DALLAS, May 27 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), (http://www.accesspharma.com) announced today that
|
| EUSA Pharma Completes the European Launch of CAPHOSOL(R) for Prevention and Treatment of Oral Mucositis Caused by Cancer Therapy |
31st March, 2009 |
EUSA Pharma Inc |
DOYLESTOWN, Pennsylvania and OXFORD, England, March 31 /PRNewswire/ --
EUSA Pharma Inc ('EUSA'), a transatlantic specialty pharmaceutical company
focused on oncology, pain control and
|
| High-Dose Zevalin(R) With Tandem Stem Cell Infusion Produces 87 Percent Overall Survival in Relapsed/Refractory or High Risk Non-Hodgkin's Lymphoma |
20th October, 2008 |
Cell Therapeutics, Inc. |
SEATTLE, Oct. 20 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) announced today that the Journal of Clinical Oncology
has published the results of an innovative
|
| National Breast Cancer Awareness Month Shines Spotlight on Oral Mucositis as a Common Side Effect of Anticancer Therapy |
16th October, 2008 |
EUSA Pharma Inc. |
PRINCETON, N.J., Oct. 16 /PRNewswire/ -- As millions of Americans
participate in educational initiatives as part of National Breast Cancer
Awareness Month, they should keep in mind an important
|
Companies working in the area of Mucositis from Bioportfolio's Biocorporate database : | |
| Company Name | |
Alizyme is a drug development company. It develops new products to treat diseases with high unmet medical need and substantial market opportunity. To date it has focussed on obesity and related...
www.alizyme.co.uk/ View full profile
| |
IntraBiotics' mission is to combine clinical development with recognized commercial expertise for the development and commercialization of emerging drugs and commercial products. To achieve that...
www.apothogen.com/ View full profile
| |
Cytogen is a specialty pharmaceutical company dedicated to advancing the treatment and care of cancer patients by building, developing, and commercializing a portfolio of oncology products. The...
www.cytogen.com/ View full profile
| | →View more Mucositis related companies. |
BioPortfolio Ltd. offers e-mail and postal lists for Mucositis scientists - we have details of around 427 individuals working on Mucositis .
This page has been viewed 472 times
Recent Search Terms used to find this page: oral mucositis s present in areas of gastrointestinal track | companies mucositis | oral mucositis clinical image | caphosol mouthwash | which drugs therapeutics suffer from mucositis | alizyme mucositis | mugard grade | mucositis in kaposi sarcoma | access pharmaceuticals MuGard Caphosol | .
Browse BioPortfolio's InDepth service - alphabetically:
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
or by Most Publications, recently searched for, or
most viewed.
Search for Mucositis across BioPortfolio, or for Mucositis Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH.
Thumbshots from Thumbshots.org
|
